Schistosome Vaccine Adjuvants in Experimental Research

SummaryThe current searching for broad-spectrum, effective non-toxic, and inexpensive antibilharzial medications for schistosomes vaccination and treatment in developing countries is of great interest. In addition, effective specific medications in the management of schistosomiasis transmission to avoid the possibility of development of a drug-resistant strain of the parasite. As, toll-like receptor ligands, were previously found to have (antitumor and antiviral) activities, the present study was conducted to evaluate the adjuvant effect and anti-schistosomal activity of Poly(I: C)and Zymosan against S. mansoni-infection in mice. In all experiments, animals in groups of ten mice were used for assessment of adjuvant effect and anti-schistosomal activity of the ligands. The infection of animals was done by exposure to (70-90) cercariae/mouse for about two hours. Adjuvant effect and anti-schistosomal activity of the ligands were monitored by enumeration of the worm burden, the liver and intestine eggs count in day 39 and in day 49 post-treatment.

Autorentext

Dr. Samah Kotb Nasr Eldeen is an Egyptian scientific researcher, born in Tanta city, Gharbia, Egypt. She obtained her BSc., MSc, and Ph.D. in Biochemistry from faculty of Science, Tanta University, Egypt. She published many scientific papers in different international journals and also works as a scientific reviewer at many international journals.